ZOLL’s portfolio of defibrillators receive premarket approval

  ZOLL has announced that it is the first company to achieve premarket approval (PMA) by the FDA to continue to market and distribute its full line of defibrillators in the U.S. The list of defibrillators that received PMA approval include the R Series and X Series monitor/defibrillators and the AED Pro and AED Plus automated external defibrillators.

All of these devices are equipped with ZOLL’s proprietary Rectilinear Biphasic waveform to deliver maximum current to high-impedance patients and Real CPR Help technology that helps rescuers perform high-quality CPR.

“ZOLL is very pleased to have received PMA approval for our entire portfolio of defibrillators,” said A. Ernest Whiton, President of ZOLL’s Resuscitation division. “This is the most stringent level of regulatory approval for safety and efficacy of a medical device, and represents ZOLL’s long-standing commitment to product quality, safety, and efficacy.”

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Previous Post

Mood-based features redefine comfort on the daily commute

Next Post

IoT gateway meets the demand for high speed mobile internet